Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07
  • RHEB Neddylation by UBE2F-SAG Axis Drives mTORC1 in Liver Ca

    2026-05-09

    Deciphering RHEB Neddylation: UBE2F-SAG-Mediated mTORC1 Activation in Liver Tumorigenesis

    Study Background and Research Question

    The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of cell growth, metabolism, and survival, particularly relevant in cancer biology, where its hyperactivation is commonly observed in hepatocellular carcinoma (HCC). RHEB, a small GTPase, is a well-established activator of mTORC1. However, the regulatory mechanisms controlling RHEB function, especially by post-translational modifications such as neddylation, remain incompletely understood. Neddylation—the conjugation of the ubiquitin-like protein NEDD8 to lysine residues—has been implicated in modulating protein stability and activity, yet whether RHEB is subject to neddylation and how this might influence liver cancer progression had not been previously defined (paper).

    Key Innovation from the Reference Study

    The reference study breaks new ground by identifying RHEB as a direct neddylation substrate of the UBE2F-SAG E2/E3 enzyme axis. Through a combination of in vitro and in vivo approaches, the authors demonstrate that neddylation at lysine 169 of RHEB enhances its lysosomal localization and GTP-binding affinity, both essential for robust mTORC1 signaling. This modification, previously uncharacterized for RHEB, establishes a new regulatory node in hepatic tumor biology (paper).

    Methods and Experimental Design Insights

    The research team employed a multifaceted experimental design, integrating molecular biology, biochemistry, animal genetics, and patient data analysis:
    • In vitro neddylation assays confirmed RHEB as a substrate of UBE2F-SAG. Site-directed mutagenesis at K169 established the specificity of this modification.
    • CRISPR/Cas9-mediated knockout of UBE2F in cell lines enabled loss-of-function studies, revealing effects on cell cycle and autophagy.
    • Immunoprecipitation and immunofluorescence techniques were used to monitor RHEB localization, neddylation status, and mTORC1 activity.
    • Liver-specific Ube2f knockout mice on a background of Pten deficiency modeled the impact of UBE2F on hepatic steatosis and tumorigenesis in vivo.
    • Correlation analyses between UBE2F expression and clinical outcomes in HCC patients were performed using public datasets.

    Protocol Parameters

    • assay | anti-neddylation immunoblotting | 1:2000 dilution | detection of RHEB neddylation in cell lysates | recommended by reference study (paper)
    • assay | ProBond resin affinity purification | 20 mM imidazole wash, 250 mM elution | isolation of tagged recombinant RHEB | workflow_recommendation
    • assay | CRISPR/Cas9 knockout of UBE2F | sgRNA at 50 nM | functional validation in hepatic cell lines | recommended by reference study (paper)
    • assay | immunofluorescence for lysosomal localization | 1:500 anti-RHEB, 1:1000 anti-LAMP1 | co-localization studies in HCC cells | recommended by reference study (paper)
    • assay | peptide solubility in DMSO | ≥99.8 mg/mL | optimal dissolution of synthetic tag peptides for affinity purification | product_spec

    Core Findings and Why They Matter

    The study's principal findings are:
    • UBE2F-SAG axis directly neddylates RHEB at K169, a modification required for enhanced GTP binding and lysosomal localization (paper).
    • Loss of UBE2F in cultured hepatic cells led to mTORC1 inactivation, reduced cell proliferation, and induced autophagy, highlighting the axis' importance for cell growth regulation.
    • Liver-specific deletion of Ube2f in Pten-deficient mice markedly attenuated steatosis and liver tumor development, establishing a causal link (paper).
    • Clinical data showed a correlation between high UBE2F expression/mTORC1 activity and poor HCC patient survival, suggesting translational relevance.
    These results collectively position the UBE2F-SAG-RHEB axis as a central driver of mTORC1 hyperactivation in liver cancer and a candidate therapeutic target.

    Comparison with Existing Internal Articles

    Several internal expert articles contextualize these findings for translational workflows: These resources collectively facilitate experimental reproducibility and mechanistic depth in workflows investigating protein neddylation and mTORC1 signaling.

    Limitations and Transferability

    While the study provides strong evidence for RHEB neddylation by UBE2F-SAG in hepatic cell lines and mouse models, several limitations remain:
    • Substrate specificity: The extent to which RHEB neddylation is conserved across non-hepatic tissues is not yet established (paper).
    • Therapeutic translation: While the axis is a promising target, no small-molecule UBE2F or SAG inhibitors have completed preclinical validation for HCC.
    • Patient heterogeneity: Correlative data from patient samples provide association, but causality in clinical contexts awaits further functional validation.
    Nevertheless, the mechanistic clarity gained from this study is broadly applicable to research on mTORC1 regulation, cancer metabolism, and post-translational modification networks.

    Research Support Resources

    For researchers investigating protein neddylation, mTORC1 signaling, or recombinant protein expression, robust affinity purification and detection tools are essential. The use of an X-press Tag Peptide (SKU A6010) as an N-terminal leader peptide can facilitate high-yield purification and sensitive detection of fusion proteins, supporting workflows that require precise analysis of post-translational modifications such as neddylation (internal article; product_spec). This tag peptide is compatible with affinity purification using ProBond resin and anti-Xpress antibody detection, and its high solubility and purity make it suitable for rigorous mechanistic studies. For optimal performance, researchers should consider recommended storage and handling protocols (product_spec).